Saxenda® for the treatment of obesity receives positive 14-1 vote in favour of approval from FDA Advisory Committee
2014-09-11 · Novo Nordisk A/S · original novonordisk.com ↗
Bagsværd, Denmark, 11 September 2014 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the United States Food and Drug Administration (FDA) has completed its meeting regarding the New Drug Application (NDA) for Saxenda®, the intended brand name for liraglutide 3 mg, a once-daily human GLP-1 analogue for the treatment of obesity. For further information Media: Katrine Sperling +45 3079 6718 [email protected] Ken Inchausti (US) +1 609 514 8316 [email protected] Investors: Kasper Roseeuw Poulsen +45 3079 4303 [email protected] Jannick Lindegaard Denholt +45 3079 8519 [email protected] Daniel Bohsen +45 3079 6376 [email protected] Frank Daniel Mersebach (US) +1 609 235 8567 [email protected] Company announcement No 56 / 2014
The release as fetched from its publisher. novonordisk.com ↗